Figure 5.

Protein antigen is applicable to GM-pMC-based cancer vaccine.

C57BL/6 mice were i.p. vaccinated twice with the OVA protein-loaded, or unloaded pMCs or GM-pMCs, and s.c. inoculated with MO4 tumor cells and monitored as in Figure 4a. (a) Median tumor volume. (b) Tumor growth of individual mice. (c) Kaplan-Meier survival curves. (a–c) Data shown are representative of two independent experiments. (n = 8 mice). (D) IFN-γ ELOSPOT assay ex vivo on day 56 after inoculation, as in Figure 4e. Shown are the mean ± SEM of two independent experiments (n = 7 except for pMCs). *p < .05, **p < .01, ***p < .001.